CN1479871A - 基于l1粘附分子的卵巢和子宫内膜肿瘤的诊断和治疗方法 - Google Patents

基于l1粘附分子的卵巢和子宫内膜肿瘤的诊断和治疗方法 Download PDF

Info

Publication number
CN1479871A
CN1479871A CNA018125344A CN01812534A CN1479871A CN 1479871 A CN1479871 A CN 1479871A CN A018125344 A CNA018125344 A CN A018125344A CN 01812534 A CN01812534 A CN 01812534A CN 1479871 A CN1479871 A CN 1479871A
Authority
CN
China
Prior art keywords
antibody
patient
fragment
endometrial tumors
ovary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA018125344A
Other languages
English (en)
Chinese (zh)
Inventor
�˵á������ظ�����
彼得·阿尔特福格特
米纳·福格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
German Cancer Research Center
Mor Research Applications Ltd
Original Assignee
German Cancer Research Center
Mor Research Applications Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by German Cancer Research Center, Mor Research Applications Ltd filed Critical German Cancer Research Center
Publication of CN1479871A publication Critical patent/CN1479871A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CNA018125344A 2000-07-10 2001-07-10 基于l1粘附分子的卵巢和子宫内膜肿瘤的诊断和治疗方法 Pending CN1479871A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00114788A EP1172654B1 (en) 2000-07-10 2000-07-10 Diagnostic method based on the detection of the L1 adhesion molecule for ovarian and endometrial tumors
EP00114788.3 2000-07-10

Publications (1)

Publication Number Publication Date
CN1479871A true CN1479871A (zh) 2004-03-03

Family

ID=8169210

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA018125344A Pending CN1479871A (zh) 2000-07-10 2001-07-10 基于l1粘附分子的卵巢和子宫内膜肿瘤的诊断和治疗方法

Country Status (10)

Country Link
US (2) US7618785B2 (cg-RX-API-DMAC7.html)
EP (2) EP1172654B1 (cg-RX-API-DMAC7.html)
JP (1) JP5165827B2 (cg-RX-API-DMAC7.html)
CN (1) CN1479871A (cg-RX-API-DMAC7.html)
AT (1) ATE377192T1 (cg-RX-API-DMAC7.html)
AU (1) AU2001285820A1 (cg-RX-API-DMAC7.html)
CA (1) CA2415364C (cg-RX-API-DMAC7.html)
DE (1) DE60036935T2 (cg-RX-API-DMAC7.html)
ES (1) ES2296586T3 (cg-RX-API-DMAC7.html)
WO (1) WO2002004952A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116437944A (zh) * 2020-08-03 2023-07-14 南特细胞公司 Il-15超级激动剂的药物特异性药代动力学测定

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US6852874B2 (en) 2000-10-02 2005-02-08 The Scripps Research Institute Second cycle asymmetric dihydroxylation reaction
EP1623995A1 (en) 2004-08-06 2006-02-08 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Inhibitors of L1 and ADAM10 for the treatment of carcinomas
WO2007114550A1 (en) * 2006-04-03 2007-10-11 Korea Research Institute Of Bioscience And Biotechnology A novel monoclonal antibody specific to the l1cam, a hybridoma producing the same and a method producing the same
AU2007288620B2 (en) 2006-08-23 2012-08-30 Korea Research Instititute Of Bioscience And Biotechnology A pharmaceutical composition for treating cholangiocarcinoma, a method for inhibiting growth or invasion of cholangiocarcinoma and a method for treating cholangiocarcinoma
WO2008151819A2 (en) * 2007-06-15 2008-12-18 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Treatment of tumors using specific anti-l1 antibody
AU2008201871A1 (en) * 2008-04-16 2009-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Inhibition of angiogenesis and tumor metastasis
KR20100060351A (ko) 2008-11-27 2010-06-07 한국생명공학연구원 L1cam의 활성 또는 발현을 억제하는 물질 및 항암제를포함하는 항암용 조성물
KR101504039B1 (ko) * 2012-11-16 2015-03-19 강원대학교산학협력단 인간 및 마우스 l1cam 단백질에 특이적으로 결합하는 항체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4939240A (en) * 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
GB2339200B (en) * 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
ES2296586T3 (es) * 2000-07-10 2008-05-01 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Metodo de diagnostico basado en la deteccion de la molecula de adhesion l1 para tumores de ovario y el endometrio.
US20020115065A1 (en) * 2000-08-28 2002-08-22 Ton Logtenberg Differentially expressed epitopes and uses thereof
EP1399850A2 (en) * 2001-02-21 2004-03-24 The Board of Regents of The University of Oklahoma Hla ligand database utilizing predictive algorithms and methods of making and using same

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116437944A (zh) * 2020-08-03 2023-07-14 南特细胞公司 Il-15超级激动剂的药物特异性药代动力学测定

Also Published As

Publication number Publication date
US7670601B2 (en) 2010-03-02
CA2415364C (en) 2009-02-24
WO2002004952A2 (en) 2002-01-17
DE60036935T2 (de) 2008-08-21
AU2001285820A1 (en) 2002-01-21
CA2415364A1 (en) 2002-01-17
JP5165827B2 (ja) 2013-03-21
EP1172654A1 (en) 2002-01-16
DE60036935D1 (de) 2007-12-13
US7618785B2 (en) 2009-11-17
EP1172654B1 (en) 2007-10-31
ES2296586T3 (es) 2008-05-01
JP2004513074A (ja) 2004-04-30
EP1386162A2 (en) 2004-02-04
ATE377192T1 (de) 2007-11-15
WO2002004952A3 (en) 2003-11-06
US20080138331A1 (en) 2008-06-12
US20040259084A1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US7670601B2 (en) Diagnostic and therapeutic methods based on the L1 adhesion molecule for ovarian and endometrial tumors
EP1859273B1 (en) Methods of detecting ovarian cancer
US20160153996A1 (en) B7-h1 and b7-h4 in cancer
EP2971047A1 (en) Monoclonal antibodies to transferrin and transferrin receptor antigens, and uses thereof
CN103429617B (zh) 包含抗-ck8/18复合物自身抗体的标记物及其诊断癌症的用途
US20130058966A1 (en) Anti-pdef antibodies and uses thereof
CN109633165B (zh) 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用
JP2007507695A (ja) 乳癌に対するマーカーとしてのタンパク質ascの使用
JP2008502891A (ja) 乳癌のマーカーとしてのタンパク質pdx1の使用
JP4292208B2 (ja) 乳癌に対するマーカーとしてのタンパク質speeの使用
WO2007075672A2 (en) Prognostic cancer markers
KR20210109724A (ko) 암의 진단용 조성물
JP2008035836A (ja) 腫瘍マーカー
KR102433986B1 (ko) 암의 진단용 조성물
KR102280360B1 (ko) 암의 진단용 조성물
JP2004198313A (ja) 甲状腺腫瘍の診断用キット
KR101240199B1 (ko) 대장암 줄기세포 선별용 단백질성 마커
WO2002006515A2 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20050100955A1 (en) Method of diagnosing, monitoring, staging, imaging and treating colon cancer
US20040053344A1 (en) Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof
EP1621637A1 (en) ppGalNac-T6 mRNA or peptide as a new marker for the detection of cancer cells
US7928188B2 (en) Antigen polypeptide for the diagnosis and/or treatment of ovarian cancer
JP5562738B2 (ja) 子宮体部類内膜腺癌の予後判定方法
KR20210080694A (ko) 암의 진단용 조성물
EP1245675A1 (en) Cancer cell-specific HLA-F antigen and a diagnostic method of cancer by using thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication